INNOVATION PHARMACEUTICALS INC News

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

GlobeNewswireAug 28, 2023 20:00

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

GlobeNewswireJun 21, 2023 20:00

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing

GlobeNewswireJun 5, 2023 22:00

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

kopsourceApr 20, 2023 04:43

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications

GlobeNewswireApr 17, 2023 20:05

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

GlobeNewswireMar 15, 2023 20:03

Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter Into a Definitive Strategic Development Agreement

GlobeNewswireJan 9, 2023 20:35

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis

GlobeNewswireDec 13, 2022 20:31

Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family

GlobeNewswireNov 28, 2022 22:05

NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"

GlobeNewswireOct 26, 2022 21:35

Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin

GlobeNewswireOct 4, 2022 19:36

Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform

AccesswireSep 13, 2022 19:35

Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox

AccesswireAug 5, 2022 21:35

Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate

AccesswireJul 22, 2022 19:35

Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers

AccesswireJun 23, 2022 19:35

Innovation Pharma acquires minority stake in Israeli med-tech company Squalus

Seeking AlphaJun 15, 2022 23:04

Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology

AccesswireJun 15, 2022 22:35

Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases

AccesswireMar 7, 2022 20:40

Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022

AccesswireDec 7, 2021 20:34

Innovation Pharmaceuticals Provides Brilacidin Program Update

AccesswireNov 18, 2021 21:36